Researchers sought to determine whether subcutaneous isatuximab would be an effective treatment for patients with RRMM.
Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how ...
Sometimes, the best way to achieve a big outcome is to start small. That principle is at the center of new work from a ...
Subcutaneous vedolizumab dose intensification restored steroid-free clinical response in approximately one-third of patients with IBD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback